Preparing for the future of rare diseases

Advances in Experimental Medicine and Biology

Volumn 1031, Issue , 2017, Pages 641-648

  Groft, Stephen C ^a   Posada de la Paz, Manuel ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Mobile health technologies; Orphan products; Patient centric research; Rare diseases; Telehealth; Telemedicine; Transitional care; Value based care

Indexed keywords

ORPHAN DRUG;

ADVOCACY GROUP; DISEASE COURSE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH SERVICE; HUMAN; MEDICAL DECISION MAKING; MEDICATION COMPLIANCE; PATIENT ADVOCACY; PATIENT CARE; PATIENT PARTICIPATION; PERSONALIZED MEDICINE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RARE DISEASE; TELEHEALTH; TELEMEDICINE; THERAPEUTIC RESEARCH; TRANSITIONAL CARE; DRUG MANUFACTURE; ECONOMICS; FINANCIAL MANAGEMENT; FORECASTING; HEALTH CARE DELIVERY; MASS COMMUNICATION; MEDICAL RESEARCH; TRENDS; VALUE-BASED INSURANCE DESIGN;

BIOMEDICAL RESEARCH; DELIVERY OF HEALTH CARE; DIFFUSION OF INNOVATION; FORECASTING; HEALTH CARE COSTS; HUMANS; ORPHAN DRUG PRODUCTION; RARE DISEASES; RESEARCH SUPPORT AS TOPIC; TELEMEDICINE; VALUE-BASED INSURANCE;

EID: 85037642906     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-67144-4_34     Document Type: Chapter

References (9)

1. Clinical trials transformation initiative recommendations: effective engagement with patient groups around clinical trials. www.ctti-clinicaltrials.org
2. Elf M, Flink M, Nilsson M, Tistad M, von Koch L, Ytterberg C (2017) The case of value-based healthcare for people living with complex long-term conditions. BMC Health Serv Res 17(1): 24. https://doi.org/10.1186/s12913-016-1957-6
3. Kenney J (2016) Value-based care must be linked to improved clinical outcomes. Am Health Drug Benefits 9(Spec Issue): 22
4. Moloney C (2016) Meeting the challenges of rare disease treatment adherence. Pharmaforum. http://pharmaphorum.com/views-and-analysis/meeting-challenges-rare-disease-treatmentadherence/, August 9
5. Patient Groups & Clinical Trials project. https://www.ctti-clinicaltrials.org/briefing-room/recommendations/ ctti-recommendations-effective-engagement-patient-groups-around, October 2015
6. Pediatric to Adult Care Transitions Initiative, American College of Physicians, https://www. acponline.org/clinical-information/high-value-care/resources-for-clinicians/pediatric-toadult- care-transitions-initiative
7. The 21st Century Cures Act, United States Public Law 114-255, (2016). December 13
8. Wollins DS, Zafar SY (2016) A touchy subject: can physicians improve value by discussing costs and clinical benefits with patients? Oncologist 21(10): 1157-1160. Published online 2016 Aug 22. doi: https://doi.org/10.1634/theoncologist.2016-0207
9. Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, Abernethy AP (2013) The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. The Oncologist 18: 381-390